关注的新型 SARS-CoV-2 变体和潜在的干预方法。
Emerging SARS-CoV-2 variants of concern and potential intervention approaches.
机构信息
Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Room 619, LKSKI, 30 Bond Street, Toronto, ON, M5B1W8, Canada.
Department of Internal Medicine D, Rambam Health Care Campus, Haifa, Israel.
出版信息
Crit Care. 2021 Jul 12;25(1):244. doi: 10.1186/s13054-021-03662-x.
Abstract
The major variant of concerns (VOCs) have shared mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins, mostly on the S1 unit and resulted in higher transmissibility rate and affect viral virulence and clinical outcome. The spike protein mutations and other non-structural protein mutations in the VOCs may lead to escape approved vaccinations in certain extend. We will discuss these VOC mutations and discuss the need for combination therapeutic strategies targeting viral cycle and immune host responses.
摘要
主要关切的变异株（VOCs）在严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白上具有共享突变，主要在 S1 单位，导致更高的传染性，并影响病毒毒力和临床结果。VOCs 中的刺突蛋白突变和其他非结构蛋白突变可能在一定程度上导致已批准疫苗的逃逸。我们将讨论这些 VOC 突变，并讨论针对病毒周期和宿主免疫反应的联合治疗策略的必要性。
相似文献
1
Emerging SARS-CoV-2 variants of concern and potential intervention approaches.
Crit Care. 2021 Jul 12;25(1):244. doi: 10.1186/s13054-021-03662-x.
2
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
Microbiol Spectr. 2022 Apr 27;10(2):e0273221. doi: 10.1128/spectrum.02732-21. Epub 2022 Mar 30.
3
Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein.
Water Res. 2021 Jun 1;197:117104. doi: 10.1016/j.watres.2021.117104. Epub 2021 Apr 2.
4
SARS-CoV-2 variants - Evolution, spike protein, and vaccines.
Biomed J. 2022 Aug;45(4):573-579. doi: 10.1016/j.bj.2022.04.006. Epub 2022 May 6.
5
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
J Korean Med Sci. 2021 May 10;36(18):e124. doi: 10.3346/jkms.2021.36.e124.
6
SARS-CoV-2's Variants of Concern: A Brief Characterization.
Front Immunol. 2022 Jul 26;13:834098. doi: 10.3389/fimmu.2022.834098. eCollection 2022.
7
Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
Microbiol Spectr. 2022 Feb 23;10(1):e0251321. doi: 10.1128/spectrum.02513-21.
8
SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.
Int J Mol Sci. 2021 Mar 17;22(6):3060. doi: 10.3390/ijms22063060.
9
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.
10
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
引用本文的文献
1
Tracing the evolutionary pathway of SARS-CoV-2 through RNA sequencing analysis.
Sci Rep. 2025 Jul 4;15(1):23961. doi: 10.1038/s41598-025-09911-1.
2
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.
Vet Q. 2025 Dec;45(1):1-20. doi: 10.1080/01652176.2025.2509506. Epub 2025 May 28.
3
Identification of Significant Mutations in Spike Protein of SARS-CoV-2 Variants of Concern and the Discovery of Potent Inhibitors.
Glob Health Epidemiol Genom. 2025 Apr 28;2025:5042190. doi: 10.1155/ghe3/5042190. eCollection 2025.
4
Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort.
Vaccines (Basel). 2025 Jan 29;13(2):143. doi: 10.3390/vaccines13020143.
5
Immunogenicity of virus-like particle vaccine candidates against SARS-CoV-2 infection.
Access Microbiol. 2025 Feb 17;7(2). doi: 10.1099/acmi.0.000925.v3. eCollection 2025.
6
Impact of African-Specific ACE2 Polymorphisms on Omicron BA.4/5 RBD Binding and Allosteric Communication Within the ACE2-RBD Protein Complex.
Int J Mol Sci. 2025 Feb 6;26(3):1367. doi: 10.3390/ijms26031367.
7
evaluation of and extract activity against SARS-CoV-2 Delta variant in Golden Syrian hamsters: Potential herbal alternative for COVID-19 treatment.
J Tradit Complement Med. 2024 May 16;14(6):598-610. doi: 10.1016/j.jtcme.2024.05.004. eCollection 2024 Nov.
8
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins.
Curr Med Chem. 2025;32(19):3790-3824. doi: 10.2174/0109298673323348241208080419.
9
Immunogenicity of two-dose sinopharm BBIB-CorV vaccine in Morocco: One-year follow-up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern.
Immun Inflamm Dis. 2024 Nov;12(11):e1359. doi: 10.1002/iid3.1359.
10
Shift in Demographic Involvement and Clinical Characteristics of COVID-19 From Wild-Type SARS-CoV-2 to the Delta Variant in the Indian Population: In Silico Analysis.
Interact J Med Res. 2024 Oct 8;13:e44492. doi: 10.2196/44492.
本文引用的文献
1
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
Nat Commun. 2021 Oct 20;12(1):6097. doi: 10.1038/s41467-021-26354-0.
2
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.
Lancet Infect Dis. 2021 Aug;21(8):1070. doi: 10.1016/S1473-3099(21)00262-0. Epub 2021 May 19.
3
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Cell. 2021 Jun 24;184(13):3426-3437.e8. doi: 10.1016/j.cell.2021.04.025. Epub 2021 Apr 20.
4
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
Cell. 2021 May 13;184(10):2587-2594.e7. doi: 10.1016/j.cell.2021.03.052. Epub 2021 Mar 30.
5
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
Nature. 2021 May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x. Epub 2021 Mar 25.
6
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.
7
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
8
Neutralizing Activity of BNT162b2-Elicited Serum.
N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.
9
Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.
iScience. 2021 Mar 19;24(3):102254. doi: 10.1016/j.isci.2021.102254. Epub 2021 Mar 1.
10
Antiviral peptides against Coronaviridae family: A review.
Peptides. 2021 May;139:170526. doi: 10.1016/j.peptides.2021.170526. Epub 2021 Mar 4.
Zotero 插件